Integrated Rapid Mycoplasma Detection from Extraction to Result: A New Choice for NAT Testing of Extraneous Agents in Cell Therapy QC

26

2026.06

Antibiotics Overseas Compliance: Focus on Non-Endotoxin Pyrogen Control and Key Requirements for MAT Assay

24

2026.06

Compliance Guideline for Monocyte Activation Test (MAT)

22

2026.06

Quality of Mycoplasma Strains: A Key Factor Determining the Reliability of Limit of Detection (LOD) for Nucleic Acid Amplification Assays

18

2026.06

Upgrading HCD Quality Control for Biologics: A Scientific Risk Control Transformation from Total Quantity Limitation to Fragment Analysis

17

2026.06

Research Supports Influenza Vaccine Safety: Analytical Method for Host Cell Residual DNA Fragments in H5N1 Inactivated Whole-Virus Influenza Vaccine

16

2026.06

From ELISA to LC-MSMS Dual-Platform Strategy and Industry Trends for Residual Host Cell Protein (HCP) Detection

10

2026.06